Shude Cui

1.6k total citations
42 papers, 610 citations indexed

About

Shude Cui is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shude Cui has authored 42 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 26 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shude Cui's work include Breast Cancer Treatment Studies (19 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (9 papers). Shude Cui is often cited by papers focused on Breast Cancer Treatment Studies (19 papers), HER2/EGFR in Cancer Research (12 papers) and Cancer Treatment and Pharmacology (9 papers). Shude Cui collaborates with scholars based in China, Taiwan and United States. Shude Cui's co-authors include Zhenzhen Liu, Hengwei Zhang, Chongjian Zhang, Min Yan, Dechuang Jiao, Huijie Fan, Qin Li, Jianghua Qiao, Yuping Ye and Tao Sun and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Molecular Cancer.

In The Last Decade

Shude Cui

39 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shude Cui China	14	290	276	233	139	56	42	610
Alessandra Bulotta Italy	14	406 1.4×	124 0.4×	264 1.1×	249 1.8×	52 0.9×	47	695
Magali Castells France	9	254 0.9×	203 0.7×	279 1.2×	68 0.5×	24 0.4×	9	723
Xiaoxiang Rong China	14	283 1.0×	415 1.5×	473 2.0×	168 1.2×	24 0.4×	28	859
Gemma Shay United States	9	320 1.1×	242 0.9×	299 1.3×	72 0.5×	24 0.4×	10	637
Kateřina Bouchalová Czechia	12	229 0.8×	128 0.5×	193 0.8×	62 0.4×	24 0.4×	35	486
Wanja Kildal Norway	14	149 0.5×	149 0.5×	214 0.9×	188 1.4×	38 0.7×	37	625
Cristina Nieto‐Jiménez Spain	16	464 1.6×	137 0.5×	456 2.0×	139 1.0×	63 1.1×	40	942
Fanny Bouquet France	12	258 0.9×	154 0.6×	355 1.5×	87 0.6×	55 1.0×	17	589
Paola Bianca Italy	5	322 1.1×	204 0.7×	341 1.5×	105 0.8×	20 0.4×	6	639
Qilai Long China	16	150 0.5×	169 0.6×	422 1.8×	248 1.8×	34 0.6×	34	798

Countries citing papers authored by Shude Cui

Since Specialization

Citations

This map shows the geographic impact of Shude Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shude Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shude Cui more than expected).

Fields of papers citing papers by Shude Cui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shude Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shude Cui. The network helps show where Shude Cui may publish in the future.

Co-authorship network of co-authors of Shude Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Shude Cui. A scholar is included among the top collaborators of Shude Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shude Cui. Shude Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Qingyuan, Wei Li, Xichun Hu, et al.. (2023). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial. PubMed. 4. 18–18. 4 indexed citations

Wang, Jiayu, Li Cai, Yanqiu Song, et al.. (2023). Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). European Journal of Cancer. 184. 73–82. 7 indexed citations

Sun, Yadong, Peili Wang, Jianghua Qiao, et al.. (2023). A Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy. Medical Science Monitor. 29. e940124–e940124. 1 indexed citations

Niu, Limin, et al.. (2023). Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10‐year, single‐center, real‐world study of 67 cases. Cancer Medicine. 12(9). 10672–10683. 3 indexed citations

Xu, Binghe, Huiping Li, Zefei Jiang, et al.. (2022). Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China. Chinese Journal of Cancer Research. 34(3). 592–600. 2 indexed citations

Niu, Limin, et al.. (2021). Clinical diagnosis and treatment of breast cancer with brain metastases and establishment of a prognostic model: a 10-year, single-center, real-world study of 559 cases. Annals of Translational Medicine. 9(16). 1331–1331. 6 indexed citations

Ma, Li, Shude Cui, Peifen Fu, et al.. (2020). Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China. Scientific Reports. 10(1). 18132–18132. 9 indexed citations

Yuan, Peng, Xichun Hu, Tao Sun, et al.. (2019). Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. European Journal of Cancer. 112. 57–65. 68 indexed citations

Zhang, Chongjian, Lu Wang, Lina Wang, & Shude Cui. (2016). A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis. BioDrugs. 30(1). 33–40. 1 indexed citations

10.

Liu, Miao, Shu Wang, Shude Cui, et al.. (2015). The feasibility of the ACOSOG Z0011 Criteria to Chinese Breast Cancer Patients: A Multicenter Study. Scientific Reports. 5(1). 15241–15241. 15 indexed citations

11.

Huang, Liang, Sheng Chen, Wentao Yang, et al.. (2015). Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. Oncotarget. 6(21). 18683–18692. 20 indexed citations

12.

Qiao, Jianghua, et al.. (2014). Association of methylenetetrahydrofolate reductase and methionine synthase polymorphisms with breast cancer risk and interaction with folate, vitamin B6, and vitamin B12 intakes. Tumor Biology. 35(12). 11895–11901. 37 indexed citations

13.

Yang, Hua, Chongjian Zhang, & Shude Cui. (2014). Expression of hepatocyte growth factor in breast cancer and its effect on prognosis and sensitivity to chemotherapy. Molecular Medicine Reports. 11(2). 1037–1042. 11 indexed citations

14.

Yan, Min, et al.. (2014). Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer.. PubMed. 26(6). 692–7. 8 indexed citations

15.

Yan, Min, Huimin Lü, Zhenzhen Liu, et al.. (2013). High risk factors of brain metastases in 295 patients with advanced breast cancer. Chinese Medical Journal. 126(7). 1269–1275. 14 indexed citations

16.

Ye, Yuping, et al.. (2012). miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncology Letters. 4(5). 1027–1032. 45 indexed citations

17.

Yan, Min, Hongyan Huang, Ting Wang, et al.. (2011). Dysregulated Expression of Dicer and Drosha in Breast Cancer. Pathology & Oncology Research. 18(2). 343–348. 51 indexed citations

18.

Zhang, Sheng, Chongjian Zhang, Jingjing Liu, et al.. (2011). A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer. Medical Oncology. 29(2). 479–485. 2 indexed citations

19.

Cui, Shude, Zhenzhen Liu, Hui Liu, et al.. (2005). [The relationship between 99mTc-MIBI scintimammography of breast cancer and multidrug-resistant proteins].. PubMed. 27(10). 606–8. 1 indexed citations

20.

Liu, Zhenzhen, Hengwei Zhang, Bing Wei, & Shude Cui. (2004). [Correlation of expression of heparanase to angiogenesis and prognosis of breast cancer].. PubMed. 23(11). 1342–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact